Figure 2
Ba/F3-VEGFR2 proliferate on hVEGF and mIL3 and hVEGF-driven cell proliferation can be inhibited by the addition of bevacizumab. Ba/F3-VEGFR2 cells proliferate dose dependently on hVEGF. Cell proliferation is calculated relative to hVEGF 10 ng ml−1 (A). Ba/F3-VEGFR2 cells proliferate dose dependently on mIL3. Cell proliferation is calculated relative to mIL3 10 ng ml−1 (B). Co-incubation of a fixed hVEGF concentration (1.25 ng ml−1) with a titration range of bevacizumab induces a dose-dependent proliferation inhibition of Ba/F3-VEGFR2 cells, whereas total human Ig does not inhibit VEGF driven Ba/F3-VEGFR2 cell proliferation (C). Bevacizumab does not inhibit mIL3 driven Ba/F3-VEGFR2 cell proliferation (D). Data are expressed as mean± (s.d.) of 3 independent experiments except for the experiment with total human Ig in which data shown represent mean±s.d. of triplicate wells of 1 experiment. *P<0.05, **P<0.01, ***P<0.001.
